Danaher delivered a strong finish to 2025, beating expectations with Q4 sales of $6.8 billion and core revenue growth of 2.5%. For the full year, the company reported sales of $24.6 billion (core growth of 2%) and adjusted diluted EPS of $7.80, up 4.5%. A key highlight was the generation of $5.3 billion in free cash flow, representing a 145% conversion rate and marking the 34th consecutive year of exceeding 100% conversion. Performance was driven by robust bioprocessing demand (high single-digit growth) and improving momentum in diagnostics, partially offset by softness in life sciences academic end markets. Looking ahead to 2026, management provided guidance for core revenue growth of 3% to 6% and adjusted EPS of $8.35 to $8.50, anticipating continued recovery in pharma and stable biotech demand.
| Metric | Value | Change |
|---|---|---|
| Q4 2025 Sales | $6.8 billion | Reported in quarter; Core revenue +2.5% year-over-year |
| Full Year 2025 Sales | $24.6 billion | Core revenue +2% year-over-year |
| Full Year 2025 Adjusted EPS | $7.80 | +4.5% year-over-year |
| Q4 2025 Adjusted EPS | $2.23 | +4% year-over-year |
| Full Year 2025 Free Cash Flow | $5.3 billion | Conversion ratio of 145% (exceeded 100% for 34th consecutive year) |
| Q4 2025 Adjusted Operating Profit Margin | 28.3% | Down 130 basis points year-over-year |
| Bioprocessing Core Revenue Growth (Q4) | High Single Digits | Driven by robust demand for commercialized therapies |
| Respiratory Revenue (Q4) | Approximately $500 million | Exceeded expectations due to active respiratory season |
Bioprocessing Durability and Reshoring: Management emphasized the long-term strength of the bioprocessing market, citing that underlying biologic demand has grown at double-digit rates annually for over a decade. A key strategic signal is the focus on 'reshoring,' where Rainer Blair noted that U.S. reshoring-related greenfield investments are expected to provide incremental upside over time. This is supported by a third consecutive quarter of sequential equipment order growth, suggesting a potential inflection point in capital spending.
Innovation as a Growth Driver: Danaher is leveraging its R&D to drive approximately 25% year-over-year growth in new product revenue. Specific innovations like the Cytiva AcelRx X platform bioreactor and the Cepheid Expert GI panel are not just product launches but strategic moves to capture share in high-growth areas like biologics manufacturing and multiplex diagnostics. This focus on high-value innovation supports margin expansion and pricing power.
Operational Discipline and Margin Expansion: Despite a 130 basis point decline in Q4 margins due to tariffs and investments, management signaled confidence in margin expansion for 2026. They cited $250 million in cost actions (benefiting EPS by ~$0.30) and the rightsizing of operations (e.g., at Abcam) as key levers. The ability to maintain high conversion rates (145%) amidst inflation highlights the power of the Danaher Business System (DBS) to offset macro pressures.
M&A Readiness: With a strong balance sheet (Debt/EBITDA < 2x) and improving free cash flow, Danaher is signaling a readiness to deploy capital. Rainer Blair described the M&A environment as 'more constructive' with valuations moving in the 'right direction.' This suggests a strategic pivot from pure cost-cutting and integration to pursuing tuck-in acquisitions that bolster their high-growth platforms, particularly in Life Sciences and Diagnostics.
Margin Pressure and Cost Headwinds: Despite the strong top-line finish, Q4 adjusted operating profit margins fell 130 basis points year-over-year to 28.3%. Management attributed this to cost savings initiatives not fully offsetting tariff-related cost pressures and significant productivity investments. While they expect margin recovery in 2026, the persistent impact of tariffs and the need for continued investment pose a risk to near-term profitability.
Life Sciences End Market Weakness: The Discovery and Medical segment experienced a core revenue decline, driven by difficult comparisons and 'funding constraints' in academic research. Management noted that academic and government demand remained 'muted' and could face 'choppiness' due to policy discussions. This softness in a historically stable segment indicates that the broad-based recovery in Life Sciences is lagging behind Bioprocessing and Diagnostics.
China Market Uncertainty: While high-growth markets outside of China were strong, China itself posted a low single-digit decline. Management cited 'volume-based procurement headwinds' in diagnostics and noted that while bioprocessing in China is strengthening, it is coming off a large comp. The reliance on policy changes moderating for growth to return introduces a degree of political and regulatory risk to the 2026 outlook.
Equipment Order Visibility: While management celebrated the return to equipment revenue growth and sequential order increases, they remained cautious, stating, 'one quarter [of growth] a trend does not make.' The guidance assumes equipment will be flat for 2026, implying that management does not yet have full visibility or confidence in a sustained capital expenditure cycle, creating a risk if the anticipated 'reshoring' wave is delayed.
Overall: Management exhibited a confident and disciplined demeanor throughout the call, frequently using terms like 'strong finish,' 'encouraged,' and 'better-than-expected.' Rainer Blair and Matt McGrew were direct in their assessment of the market, acknowledging headwinds in academic funding and China while emphasizing the resilience of the bioprocessing and diagnostics franchises. The tone shifted from cautious in previous quarters to a more optimistic outlook regarding the sustainability of the recovery, particularly around pharma R&D and equipment orders.
Confidence: HIGH - Management provided specific quantitative guidance for 2026, detailed color on order books, and articulated clear drivers for upside. Their confidence was bolstered by 'better-than-expected' Q4 results and 'encouraging' trends in end markets, leading them to reaffirm long-term growth frameworks.
Management anticipates core revenue growth in the range of 3% to 6%. This outlook assumes bioprocessing growth will be similar to 2025 (high single digits), a modest improvement in Life Sciences end markets (remaining below historical levels), and higher growth in Diagnostics as China headwinds moderate.
The company initiated guidance in the range of $8.35 to $8.50. This implies growth of approximately 7-9% over the prior year's $7.80, driven by an estimated $0.30 benefit from 2025 cost actions and core revenue growth at the low end of the 3-4% range.
Expected to be up low single digits.
Expected to be approximately 28.5%.
Expected to be approximately $1.8 billion for the full year, assuming a normal respiratory season and consistent testing protocols.
Hedging & Uncertainty: Management utilized hedging language to balance optimism with prudence, particularly regarding the sustainability of the recovery. Phrases like 'we anticipate,' 'we expect,' and 'assuming' were prevalent when discussing 2026 guidance. For example, Matt McGrew stated, 'We are assuming the low end of the core growth... If we do better from a core growth perspective, there's probably likely some upside here to EPS.' Rainer Blair also tempered expectations on equipment, noting, 'While orders remain below historical levels... we are not ready to call that a trend yet.' This hedging suggests management is confident in the direction but managing investor expectations regarding the pace of acceleration.
Strong finish to the year with better-than-expected performance across the portfolio. - Rainer Blair, CEO
We are encouraged by the momentum building across our portfolio and expect growth to accelerate as end markets continue to improve. - Rainer Blair, CEO
The M&A environment is more constructive. - Rainer Blair, CEO
One quarter, a trend does not make. - Matt McGrew, CFO
We are assuming the low end of the core growth... If we do better from a core growth perspective, there's probably likely some upside here to EPS. - Matt McGrew, CFO
Underlying biologic demand... has grown at double-digit rates annually for more than a decade. - Rainer Blair, CEO
Analyst Sentiment: Analysts were generally inquisitive and focused on the sustainability of the recovery, particularly in Bioprocessing and Life Sciences. Questions from firms like Bank of America, Jefferies, and Melius Research probed the conservatism in the guidance and the specific drivers for upside. There was a notable interest in the M&A landscape and the readiness of the balance sheet for deployment.
Management Responses: Management responses were detailed and transparent, often breaking down the math behind the guidance (e.g., Matt McGrew's explanation of the EPS bridge). Rainer Blair provided qualitative color from customer visits to validate the 'reshoring' thesis. They were direct about the 'choppiness' in academic funding but remained firm on their positive outlook for the pharma and bioprocessing end markets.
Bioprocessing Orders and Equipment Cycle: Analysts sought clarity on the order book and whether the Q4 equipment growth signaled a broader capex recovery. Management confirmed sequential order growth but remained cautious, guiding for flat equipment performance in 2026 until a clearer trend emerges.
Life Sciences Recovery: There was significant focus on the 'gradual improvement' in Life Sciences, specifically the divergence between recovering pharma demand and muted academic spending. Management highlighted Abcam's turnaround and the stabilization of clinical/applied markets as key positives.
M&A and Capital Allocation: With a strong balance sheet, analysts asked about the readiness for M&A. Management confirmed the environment is 'more constructive' and they are actively cultivating opportunities, though they remain disciplined on valuation and strategic fit.
China and Respiratory Assumptions: Analysts asked for details on the 2026 respiratory revenue assumption ($1.8B) and the trajectory of the China business. Management explained that the respiratory figure is based on 'endemic' levels and expects China headwinds to moderate as the year progresses.
Danaher Corporation remains a premier, high-quality compounder in the life sciences and diagnostics tools space. The company's Q4 performance demonstrated the resilience of its business model, generating elite free cash flow conversion (145%) despite macroeconomic headwinds. The investment thesis is underpinned by three core pillars: 1) The durable growth of the Bioprocessing franchise, driven by the secular shift to biologics and the emerging trend of reshoring manufacturing to the U.S.; 2) The innovation engine at Cytiva and Cepheid, which is driving 25% growth in new product revenue and gaining market share; and 3) The operational discipline of the Danaher Business System, which is enabling margin expansion through cost savings and productivity gains even as it invests in R&D. Critical factors for success include the sustained recovery in pharma R&D spending and the execution of the $250 million cost savings program to drive EPS growth. While risks remain regarding academic funding softness and China policy headwinds, the valuation appears supported by the company's strong balance sheet and the potential for M&A to accelerate growth. The guidance for 3-6% core growth and 7-9% EPS growth provides a solid baseline, with significant upside potential if equipment orders normalize faster than anticipated. We recommend buying Danaher for its defensive cash flows and leveraged exposure to the long-term growth of the healthcare sector.
The transcript highlights a significant macro trend of 'reshoring' in the pharmaceutical supply chain. Rainer Blair noted that 'U.S. reshoring-related greenfield investments expected to provide incremental upside over time.' This indicates a structural shift where pharmaceutical companies are moving manufacturing capacity back to the U.S. to secure supply chains, reversing years of offshoring. This trend benefits domestic capital equipment suppliers like Danaher and suggests a sustained, multi-year investment cycle in U.S. biomanufacturing infrastructure.
The 'Golden Age of Biologics' continues to expand, with management noting that 'global biologic revenues [have] surpass[ed] small molecule drugs for the first time.' Furthermore, 'biologics expected to represent more than two-thirds of the top 100 drugs by 2030.' This macro shift in the pharmaceutical industry towards complex biologics necessitates advanced manufacturing technologies, creating a long-term tailwind for the bioprocessing equipment and consumables market that Danaher leads.
Management provided insight into the 'endemic' state of respiratory viruses, which impacts the diagnostics market. They revised their assumption for respiratory revenue to approximately $1.8 billion for 2026, based on a 'normal respiratory season.' This suggests that the massive volatility in testing demand seen during the acute phase of the pandemic has normalized into a predictable, seasonal pattern, allowing for more stable forecasting in the molecular diagnostics segment.